ShineWay Medical's Intracranial Balloon Dilatation Catheter Receives NMPA Approval for Market Launch

Source of the article:HeartCare

Reprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.

HeartCare Future

On December 8, 2023, HeartCare's self-developedHeartCare·Light Swallow Low-Pressure IntracranialBalloon Dilation Catheter(GXZZ20233031890) has been approved for marketing by the National Medical Products Administration. With the approval of this intracranial balloon dilation catheter, HeartCare further enhances its treatment solutions for neurovascular stenosis, helping more patients maintain vascular health.

HeartCare·Light SwallowIntracranial Balloon Dilation Catheter:

1. Lower pressure value

Nominal pressure 3atm, rated burst pressure 12atm

2. Better in place

Ultra-smooth hydrophilic coating extends to the balloon surface, ensuring smooth positioning and direct access to the lesion.

3. A wider range of models

117 specifications and models to meet various size requirements for clinical surgeries.

4. Higher Safety

Reliable expansion, Pebax material combined with low-pressure inflation, reducing intraoperative complications

HeartCare·Light SwallowIntracranial Balloon Dilation CatheterApplicable to non-acute phaseSymptomatic Intracranial Artery(Interventional treatment of atherosclerotic stenosis lesions, including the basilar artery, middle cerebral artery, intracranial segment of the carotid artery, and intracranial segment of the vertebral artery) involves expanding the narrowed lesion site by inflating a balloon to restore the vascular lumen and improve intracranial blood supply. Simple balloon dilation treatment.sICASIt may be safe and effective, and intracranial dedicated balloons and low-pressure, semi-compliant balloons can be prioritized during treatment to enhance the safety of the surgery.

HeartCare·Light SwallowSpecifications and Models of Intracranial Balloon Dilation Catheters:

Shanghai HeartCare Medical Technology Co., Ltd. (Stock Code: 06609.HK) was established in 2016. The company is committed to improving the accessibility of innovative medical technologies and safeguarding life and health. Over seven years, HeartCare has pioneered a one-stop solution for stroke treatment and prevention in China’s neurointerventional field. It boasts a full product pipeline ranging from the treatment of acute ischemic stroke and neurovascular stenosis, ischemic stroke prevention, hemorrhagic stroke treatment, to interventional access devices. The company has applied for over 300 patents, and its sales channels cover all provinces in China except Hong Kong, Macao, and Taiwan.

Building on its existing leading edge, HeartCare will continue to focus on popularizing emerging medical procedures, addressing the unmet needs of clinicians and patients in China. The company operates multiple emerging business segments, including neurointervention, full-heart treatment, peripheral intervention, and computer-assisted technologies. HeartCare aims to continuously introduce innovative interventional devices that define new procedures in these high-potential medical fields, reducing mortality rates from major diseases and improving patient outcomes.